Feed TGRNF
TG

Tong Ren Tang Technologies Co. Ltd. TGRNF OTC · Healthcare · China

$0.37 +0.00% +$0.00

Summary

68 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: ¥4.79B against ¥1.95B.
  • The share price is below the Bulios Fair Price.
  • Out of every 100 CNY of revenue, 20 CNY is left as free cash.

What to watch

  • Earnings per share fell by 13% a year over the last 3 years.
  • It earns only 4.3 CNY a year on every 100 CNY of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $0.37

By our assumptions the business is worth more than its shares cost today.

P/E today 10.4 16% lower
5-year average P/E 12.4
P/E today 10.4
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 10.4 CNY for 1 CNY of yearly profit. Over the last five years it was 12.4 CNY on average.

Valuation in detail

Is it growing?

Slowly

Revenue (CNY)

Diluted EPS (CNY)

  • Analyst estimate

Revenue grew by 6.5% a year over 5 years. Over the last 3 years it grew by 1.8% a year. Earnings per share fell by 13% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 CNY of revenue goes

Net profit, industry median (Drug Manufacturers - General) 14 CNY

Out of every 100 CNY of revenue, 5.3 CNY is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 1.7 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

High, stretched
Yield
6.46%
Paid out of profit
67%

You receive $0.02 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy